AC Immune reported a significant increase in Q3 2026 revenues and extended its cash runway into Q1 2028. Key pipeline updates include FDA Fast Track for ACI-7104 and ongoing Phase 1 trials for ACI-19764, with upcoming milestones providing potential catalysts for the stock.
AC Immune's Q3 2026 report shows a substantial increase in revenue, from CHF 0.9 million to CHF 3.2 million year-over-year, indicating improved financial performance. The company also extended its cash runway into Q1 2028, which is a positive signal for operational stability and reduces immediate funding concerns. The FDA Fast Track designation for ACI-7104 is a significant regulatory achievement, potentially accelerating its development and market entry. Upcoming milestones, such as antibody characterization for ACI-7104 and Phase 1b results for ACI-19764, offer short-term catalysts for traders. The long-term implication is the potential for these pipeline assets to address unmet medical needs in neurodegenerative diseases, but clinical trial risks remain.